KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy of argon-helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer. PMID 41229194 · Acta Oncol · 2025-Nov-12 The record describes a randomized, open-label trial in oncology patients with drug intervention (PD-1 inhibitors) and reports time-to-event efficacy endpoints (OS, PFS). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided abstract or metadata; the deterministic review flagged phase evidence as unclear. Additionally, the intervention combines a drug (PD-1 inhibitor) with a non-drug procedure (argon-helium cryoablation), which may not fit the strict 'drug-containing intervention' criterion for a pharmacological comparison. Therefore, it is excluded due to insufficient evidence for the required trial phase and potential non-drug-only intervention component.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study. PMID 41222736 · Cancer Immunol Immunother · 2025-Nov-12 The record describes a randomized, controlled trial with a drug intervention and a primary time-to-event endpoint (PFS) in human oncology. However, the trial phase is not explicitly stated in the metadata (title, abstract, publication types, or MeSH terms). Eligibility requires explicit confirmation of Phase III/IIIb or Phase II/III status. Without this, the 'phase3_or_definitive' criterion cannot be established as true, rendering the record ineligible for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial. PMID 41222702 · Cancer Immunol Immunother · 2025-Nov-12 The report is an original randomized controlled trial in oncology (rectal cancer) with a drug intervention (PD-1 blockade). However, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The primary efficacy endpoint reported is tumor response rate, which is not a time-to-event outcome. The study also includes extensive preclinical/mechanistic components (cell lines, mouse models). Therefore, it does not meet the core eligibility criterion of having a time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial. PMID 41202503 · ESMO Open · 2025-Nov The record describes an unplanned exploratory analysis from the PHERGain trial. While the parent trial is likely a definitive Phase III RCT, this specific report is a secondary analysis focusing on imaging comparisons, not the primary report of the main trial's efficacy results. The phase of the parent trial is not explicitly confirmed in the provided metadata (e.g., publication types list 'Randomized Controlled Trial' but not 'Phase III'). Therefore, eligibility cannot be fully established without confirming the primary trial's phase and that this report constitutes the original primary result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial. PMID 41193117 · Lancet Haematol · 2025-Nov The abstract explicitly states that the primary analysis demonstrated a statistically significant reduction in the risk of progression or death (a time-to-event outcome), but the reported results in the abstract are focused on patient-reported outcomes (secondary/exploratory endpoints), not the primary time-to-event efficacy analysis. Therefore, while the trial itself meets the criteria, this specific record does not present the primary time-to-event result report.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial. PMID 41075365 · ESMO Open · 2025-Nov The record describes a randomized, drug-interventional oncology trial with time-to-event endpoints, but the trial phase (III/IIIb or II/III) is not explicitly established in the provided metadata. Furthermore, the analysis presented is a secondary subgroup analysis (BMI modulation of TILs) rather than the primary report of the trial's main efficacy results. Therefore, eligibility cannot be definitively determined.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. PMID 40968753 · J Gynecol Oncol · 2025-Nov Phase of trial is not explicitly stated in provided metadata; cannot confirm if Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study. PMID 40898993 · Phytother Res · 2025-Nov The record does not provide explicit evidence that the trial is Phase III/IIIb or Phase II/III. While it is a randomized, oncology trial with drug intervention and time-to-event endpoints, the phase is not specified and cannot be assumed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Ipsilateral High Thoracic Ultrasound-Guided Erector Spinae Plane Block for Post-Thoracotomy Shoulder Pain in Thoracic Cancer Surgeries: A Randomized Controlled Clinical Trial. PMID 40841229 · J Cardiothorac Vasc Anesth · 2025-Nov The record describes a randomized controlled trial in thoracic cancer patients, but it lacks explicit Phase III classification, involves a non-drug intervention (nerve block), and does not include a time-to-event oncology efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial. PMID 40779615 · J Urol · 2025-Nov The trial is a randomized Phase III trial in oncology (bladder cancer), but it evaluates a surgical intervention (parastomal mesh placement) without a drug-containing arm. The primary endpoint is radiographic parastomal hernia rate, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier).
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients. PMID 40391840 · Afr J Reprod Health · 2025-May-16 The study is a randomized trial of trastuzumab and docetaxel in HER2+ breast cancer, but the abstract does not explicitly report a primary time-to-event efficacy endpoint (e.g., OS, PFS) with a Kaplan-Meier curve, hazard ratio, or equivalent survival analysis. 'Longer survival time' is mentioned but is vague and not formally reported as a primary time-to-event endpoint. Phase is not explicitly stated (likely Phase II/III based on design but not confirmed).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer. PMID 40222201 · Eur J Cancer · 2025-May-15 The record is an exploratory subgroup analysis of the randomized FIRE-3 study, not the primary trial report. While the underlying study is randomized and oncologic, the phase of the trial is not explicitly confirmed in this record. The report type is 'subgroup' as it analyzes a molecularly defined subset.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial. PMID 40346479 · BMC Cancer · 2025-May-09 The record describes a protocol for a non-randomized, surgical (non-drug) trial in HCC with no time-to-event efficacy results. It fails multiple key eligibility criteria: randomization, drug intervention, definitive phase, time-to-event endpoints, and original results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. PMID 40147846 · J Nucl Med · 2025-May-01 The study is a randomized controlled trial in oncology (prostate cancer) with a drug intervention, but it is not eligible because the primary outcome is not a time-to-event endpoint with reported KM/HR analysis, and the phase is not explicitly confirmed as Phase III. The report is a secondary subgroup analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: A single-blind phase III multicentre randomized controlled trial (FLUOCOL-01/FRENCH 21/GRECCAR 19 intergroup trial). PMID 40415381 · Colorectal Dis · 2025-May This is a Phase III randomized controlled trial protocol for a diagnostic/procedural intervention (indocyanine green fluorescence angiography) in colorectal surgery. The primary endpoint is anastomotic leak (a complication), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It does not meet the required drug intervention or time-to-event endpoint criteria, and it is a protocol without reported results.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA. PMID 40270251 · Future Oncol · 2025-May Title indicates an oncology drug study, but the provided metadata (title, publication types, keywords, deterministic review) does not explicitly establish the presence of a time-to-event efficacy endpoint, randomization, phase, human subject status, or that this is an original result report. The record is a 'plain language summary' which is not a formal primary result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors. PMID 40174385 · Lung Cancer · 2025-May Cannot confirm primary/key secondary time-to-event efficacy endpoint from provided metadata; requires review of full text.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. PMID 40065169 · Nat Med · 2025-May The study is a randomized phase 3 trial in oncology (myelofibrosis) with a drug intervention, but the reported endpoints are not time-to-event efficacy outcomes (e.g., OS, PFS). The primary endpoint is spleen volume reduction, and secondary endpoints are symptom-based (TSS). No Kaplan-Meier, hazard ratio, or time-to-event analysis is mentioned, making it ineligible for the Kaplan-Meier digitization cohort.
H L
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling. PMID 40153795 · J Med Internet Res · 2025-Mar-28 The record describes a Phase III RCT, but the primary endpoint is 'relative dose intensity', not a time-to-event efficacy endpoint. The outcomes analyzed (toxicity, hospitalization, etc.) are not time-to-event efficacy metrics, and no Kaplan-Meier or HR data is reported. Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. PMID 39621965 · J Clin Oncol · 2025-Mar-20 The study is a randomized Phase III trial with a drug intervention and reports original results. However, the primary and key secondary endpoints are proportions (complete response rates), not time-to-event outcomes (OS, PFS, DFS, etc.). Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). PMID 39556015 · Circulation · 2025-Mar-04 The study is a randomized trial in cancer patients evaluating rivaroxaban duration for pulmonary embolism, but it does not meet the core eligibility criteria: it lacks a cancer-specific drug intervention for efficacy (rivaroxaban is an anticoagulant, not an anticancer therapy) and does not have a time-to-event primary efficacy endpoint (OS, PFS, DFS, etc.) as required. The primary endpoint (recurrent VTE) is a safety/thrombotic outcome, not a cancer efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial. PMID 39506905 · Haematologica · 2025-Mar-01 Cannot confirm Phase III/IIIb or Phase II/III evidence from the provided metadata. The trial is randomized, involves a drug intervention, has a time-to-event endpoint (DFS), and reports original results, but the specific trial phase is not stated in the title, abstract, or publication types. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer. PMID 39357788 · Int J Radiat Oncol Biol Phys · 2025-Mar-01 The study is an original, randomized, phase 3 oncology trial in humans. However, the primary endpoint is patient-reported quality of life (bowel health), and the intervention is radiation therapy (proton therapy vs. IMRT), not a drug-containing intervention. No time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier analysis) is reported or described as primary/key secondary. Therefore, it does not meet all criteria for inclusion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer. PMID 39954390 · ESMO Open · 2025-Mar The study is a secondary analysis of pharmacokinetics and exposure-response from a randomized trial. While it involves oncology, a human randomized trial, a drug, and a time-to-event endpoint, the metadata does not explicitly confirm the trial phase as definitive (Phase III, IIIb, or II/III). Furthermore, as a secondary analysis, it is not the primary report of the trial's efficacy comparison. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effects of narrative versus non-narrative pictorial warning labels on visual attention and alcohol-related cancer risk perceptions: An eye-tracking study. PMID 39671807 · Addict Behav · 2025-Mar The record describes a randomized eye-tracking study on alcohol warning labels and cancer risk perceptions, not a clinical trial with a drug intervention or a time-to-event efficacy endpoint. Therefore, it does not meet the core eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in non-small cell lung cancer: psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials. PMID 39636512 · Qual Life Res · 2025-Mar The report is a psychometric evaluation of patient-reported outcome (PRO) measures (PROMIS PF-SF and NSCLC-SAQ) using data from two Phase 3 trials. It does not report time-to-event efficacy outcomes (OS, PFS, etc.) or analyze drug intervention efficacy. The publication type and content indicate a methodological/psychometric study, not a primary efficacy result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer. PMID 39332930 · Eur Urol · 2025-Mar Oncology human randomized Phase III trial with original result, but excluded due to lack of time-to-event endpoint signal and apparent non-drug-only intervention (radiation fractionation comparison).
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre study. PMID 40481437 · BMC Med · 2025-Jun-06 The record describes an oncology randomized trial with a drug intervention and time-to-event endpoints. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, or publication types). The 'deterministic_review' signal 'phase3: false' indicates this criterion cannot be confirmed. Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial. PMID 40279684 · Eur J Cancer · 2025-Jun-03 The record describes a randomized, drug-intervention trial in advanced melanoma reporting time-to-event efficacy outcomes (PFS, OS), but the provided metadata does not explicitly confirm it as a Phase III/IIIb or Phase II/III trial. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, eligibility cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. PMID 40549387 · JAMA Netw Open · 2025-Jun-02 The record describes a pharmacogenomic cohort study analyzing outcomes from a randomized trial (AAML1031) and other protocols. While it contains elements of a randomized trial (AAML1031) with drug intervention and time-to-event endpoints, the abstract does not explicitly state the phase of the AAML1031 trial (Phase II, III, etc.), and the primary analysis is a retrospective pharmacogenomic validation study across multiple cohorts, not a primary report of the definitive randomized trial efficacy results. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Censoring Analysis of the INvestigating VorasiDenib In GliOma (INDIGO) Phase III Randomized Controlled Trial. PMID 39950862 · Am J Clin Oncol · 2025-Jun-01 The title indicates a Phase III randomized trial in glioma (oncology) with a drug (vorasidenib). However, the title alone ('Censoring Analysis of...') does not provide evidence of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) or a primary/original result report. The abstract is empty, offering no further data. Human subject participation and the original result status cannot be confirmed from the available metadata. Without explicit evidence of a time-to-event endpoint or a formal efficacy result report, eligibility cannot be established.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer. PMID 40409025 · Lung Cancer · 2025-Jun The record is an oncology RCT involving drug interventions and reports a time-to-event endpoint (OS hazard ratio). However, the study phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided text, and the primary focus is on developing a predictive score for treatment-related deaths, which constitutes a secondary or subgroup analysis rather than reporting the primary trial efficacy results. Therefore, eligibility cannot be fully established without confirmation of phase and primary trial report status.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer. PMID 40326044 · Future Oncol · 2025-Jun The record is a plain language summary, not an original formal-result report. The empty abstract and lack of specific trial details (phase, randomization, endpoints) in the metadata prevent establishment of required eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: Exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trial. PMID 40086561 · Photodiagnosis Photodyn Ther · 2025-Jun This is a single-arm, Phase III trial evaluating a diagnostic procedure (photodynamic diagnosis) using a drug (5-ALA) as an imaging agent for bladder cancer detection, not as a therapeutic intervention. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). PMID 40580811 · Eur J Cancer · 2025-Jul-25 The record describes a prospective cohort study (a prespecified study within a phase III trial) assessing genomic profiling agreement between primary tumors and lymph node metastases. It does not report primary efficacy results (e.g., OS, PFS, DFS) or any time-to-event endpoint from the randomized trial. It is an ancillary/translational study, not the original formal result report of a randomized trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. PMID 40696453 · Mol Cancer · 2025-Jul-22 Study meets most criteria but randomization status is not explicitly confirmed in the provided metadata; therefore, eligibility cannot be definitively determined.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. PMID 40592718 · Oncologist · 2025-Jul-04 Metadata confirms oncology, human, randomized, drug intervention, time-to-event endpoint, and original result. However, the required 'Phase III/IIIb or Phase II/III' evidence is not explicitly established in the title, abstract, or metadata, leaving 'phase3_or_definitive' as null. Without explicit confirmation of the definitive phase, eligibility cannot be set to true.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial. PMID 39584557 · Oncologist · 2025-Jul-04 The report is an oncology, human, randomized trial with a drug intervention and primary time-to-event efficacy endpoints (OS, PFS) presented as long-term final results. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract, so eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Opioid-free anaesthesia protocol based on thoracic paravertebral block enhances postoperative recovery after breast cancer surgery: A two-center, prospective, randomized, controlled trial. PMID 40532358 · J Clin Anesth · 2025-Jul The study is a randomized, prospective, multicenter trial in breast cancer surgery patients, but it compares anesthetic techniques (opioid-free vs. opioid-based) and does not involve a drug intervention for cancer treatment. The primary endpoint is a quality-of-recovery score (QoR-15), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial. PMID 39929333 · J Thorac Oncol · 2025-Jul The record is a randomized, placebo-controlled trial in human oncology with drug intervention and primary time-to-event endpoints. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types). The 'phase3_or_definitive' criterion cannot be established, making overall eligibility uncertain.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pharmacokinetics and pharmacodynamics of ciprofol after continuous infusion in elderly patients. PMID 39871139 · BMC Anesthesiol · 2025-Jan-27 Study is a randomized, controlled trial in oncology patients (undergoing gastrointestinal tumor resection) evaluating a drug (ciprofol vs propofol). However, it is not a Phase III/IIIb or Phase II/III trial (no phase specified, appears to be a pharmacokinetic/efficacy study), and it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC. PMID 39802818 · JTO Clin Res Rep · 2025-Jan The record describes a secondary analysis of a randomized trial, not the primary or definitive report of the trial's main efficacy results. The trial phase is not explicitly stated in the metadata, making it ineligible under the requirement for Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Genome analysis uncovers an inverse correlation between alterations in P21-activated kinases and patient survival across multiple cancer types. PMID 39756822 · Physiol Rep · 2025-Jan The record describes a biomarker analysis of genomic data aggregated from multiple publicly available clinical trial datasets. It does not present the primary efficacy results of a single randomized trial with a drug intervention and a time-to-event endpoint.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis. PMID 39733600 · Mult Scler Relat Disord · 2025-Jan The study is a Phase III randomized trial of fingolimod in multiple sclerosis, not an oncology study. The endpoints (relapse, MRI lesions, disability progression) are not time-to-event efficacy endpoints for human malignant neoplasm.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials. PMID 39615412 · Lung Cancer · 2025-Jan The study is an oncology Phase III randomized trial with human malignant-neoplasm (small-cell lung cancer) and reports a time-to-event efficacy endpoint (brain metastases incidence with hazard ratio). However, the intervention is non-drug (prophylactic cranial irradiation with or without hippocampal avoidance), not a drug-containing intervention. Therefore, it does not meet the drug intervention criterion.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur Urol. 86(1) (2024) 52-60]. PMID 39521695 · Eur Urol · 2025-Jan Record is a published erratum (corrigendum) to an original trial report. The abstract is empty, and no data on study population, interventions, or outcomes are provided in the record. While the title references a Phase 3 randomized trial (PSMA-SRT) with an imaging intervention (PSMA-PET/CT) for prostate cancer, it does not explicitly describe a drug-containing intervention or a time-to-event efficacy endpoint. The publication type 'Published Erratum' and lack of results content exclude it as an original result report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. PMID 39284116 · J Clin Oncol · 2025-Jan The record describes a randomized, controlled, human oncology trial with drug intervention and time-to-event efficacy endpoints (OS, RFS). However, the provided metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. Therefore, eligibility cannot be confirmed without this information.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial. PMID 40014335 · JAMA Oncol · 2025-Feb-27 The title indicates a Phase 3 randomized trial in oncology, but the provided metadata (title only) lacks explicit signals for a drug intervention (e.g., enzalutamide, abiraterone), a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.), or confirmation that this is an original result report (vs. biomarker or correlative analysis). Without the full text, eligibility cannot be established.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study. PMID 39820410 · Chin Med J (Engl) · 2025-Feb-20 Metadata (title) explicitly indicates a randomized phase 3 trial with a drug intervention for an oncology population. However, the primary endpoint is not specified as a time-to-event efficacy endpoint (e.g., OS, PFS); it appears to focus on neutropenia (a supportive care/safety outcome). The abstract is unavailable, preventing confirmation of a key efficacy endpoint, time-to-event analysis, or original result status.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparative analysis of intestinal tumor segmentation in PET CT scans using organ based and whole body deep learning. PMID 39962481 · BMC Med Imaging · 2025-Feb-17 The record is an original comparative study from a phase III randomized trial (NCT01287741) in oncology (lymphoma). However, it is not eligible because (1) it does not involve a drug intervention—it compares deep learning image segmentation methods—and (2) it does not report a time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcomes are segmentation performance metrics (Dice score, precision, recall, F1-score).
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -